67Cu-based NuriPro therapeutic (NUCLIDIUM)

N/A

Report date: 2025/11/14 17:20:10

NME

Base Information

Drug Name67Cu-based NuriPro therapeutic (NUCLIDIUM)

Drug Alias Name67Cu-based NuriPro™ therapeutic (NUCLIDIUM)67Cu-NuriPro

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Copper > 67CuRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionIonising radiation emittersProstate-Specific Membrane Antigen binders

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNuclidium AG

China Registration ClassN/A

Develop Information

Active CompaniesNuclidium AG

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A